ReviewToxins2018
Antibody Cross-Reactivity in Antivenom Research.
Review in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Computational immunology in venom research: a systematic review of epitope prediction and validation approaches.Briefings in bioinformatics · 2025Pooled it
- Immunological Cross-Reactivity and Neutralizing Efficacy of Antivenom Against Five Medically Important Iranian Viper Venoms.Veterinary medicine and science · 2026Article
- Engineering Antivenom: Research Progress and Future Directions in Snakebite Envenoming Therapy.Annals of the New York Academy of Sciences · 2026Review
- Conserved Enzymatic Peptides inInternational journal of molecular sciences · 2026Article
- Rapid, label-free surface plasmon resonance discrimination between Bothrops and Crotalus venoms using clinical antivenom as the capture reagent.PLoS neglected tropical diseases · 2026Article
- Article
- SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity.iScience · 2024Article
- Article
- Toxic Peptides from the Mexican ScorpionToxins · 2024Article
- Article
- Isolation and Functional Characterization of Erythrofibrase: An Alfa-Fibrinogenase Enzyme fromToxins · 2024Article
- Antibody-dependent enhancement of toxicity of myotoxin II from Bothrops asper.Nature communications · 2024Article
- An in vitro assay to investigate venom neurotoxin activity on muscle-type nicotinic acetylcholine receptor activation and for the discovery of toxin-inhibitory molecules.Biochemical pharmacology · 2023Article
- Unveiling the functional epitopes of cobra venom cytotoxin by immunoinformatics and epitope-omic analyses.Scientific reports · 2023Article
- Towards better antivenoms: navigating the road to new types of snakebite envenoming therapies.The journal of venomous animals and toxins including tropical diseases · 2023Article
- First Insights into the Venom Composition of Two Ecuadorian Coral Snakes.International journal of molecular sciences · 2022Article
- Clinical management of snakebite envenoming: Future perspectives.Toxicon: X · 2021Article
- The Geographic Distribution, Venom Components, Pathology and Treatments of Stonefish (Marine drugs · 2021Review
- King Cobra and snakebite envenomation: on the natural history, human-snake relationship and medical importance ofThe journal of venomous animals and toxins including tropical diseases · 2021Review
- Strategies for Heterologous Expression, Synthesis, and Purification of Animal Venom Toxins.Frontiers in bioengineering and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antivenom cross-reactivity has been investigated for decades to determine which antivenoms can be used to treat snakebite envenomings from different snake species. Traditionally, the methods used for analyzing cross-reactivity have been immunodiffusion, immunoblotting, enzyme-linked immunosorbent assay (ELISA), enzymatic assays, and in vivo neutralization studies. In recent years, new methods for determination of cross-reactivity have emerged, including surface plasmon resonance, antivenomics, and high-density peptide microarray technology. Antivenomics involves a top-down assessment of the toxin-binding capacities of antivenoms, whereas high-density peptide microarray technology may be harnessed to provide in-depth knowledge on which toxin epitopes are recognized by antivenoms. This review provides an overview of both the classical and new methods used to investigate antivenom cross-reactivity, the advantages and disadvantages of each method, and examples of studies using the methods. A special focus is given to antivenomics and high-density peptide microarray technology as these high-throughput methods have recently been introduced in this field and may enable more detailed assessments of antivenom cross-reactivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.